Xap Therapeutics
Carly Kempster is a scientist at Xap Therapeutics since February 2023, focusing on innovative delivery methods for compounds in human platelets. Previously, Carly served as a PhD student at the University of Reading from October 2019 to March 2023, working on fusogenic liposomes to enhance research methodologies while reducing animal usage, recognized with a joint award from NC3Rs and BHF. Earlier roles include Component Development Scientist at NHS Blood and Transplant, where Carly supported the development of novel treatment components and designed flow cytometry assays, and Research Assistant at the University of Cambridge, leading studies on platelet and neutrophil functions. Additionally, Carly had experience as a Trial Support Technician at Mars, beginning in May 2012, contributing to pet nutrition research.
Xap Therapeutics
1 followers
Xap Therapeutics is a start-up biotechnology company that is developing an innovative, synthetic biology-driven platform for cell therapeutics.Xap Therapeutics, formed by biotech entrepreneurs, is a producer of a "chassis" cell which functions in cell therapies through genetically engineered constructs. Xap Therapeutics wasestablished in 2017 by James Patterson, M.D., Ph.D in Cambridge, England.